Telcagepant
Telcagepant (INN) (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co..

In the acute treatment of migraine, it was found to have equal potency to rizatriptan and zolmitriptan

A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009 after the "identification of two patients with significant elevations in serum transaminases".
A memo to study locations stated that telcagepant had preliminarily been reported to increase the hepatic liver enzyme alanine transaminase (ALT) levels in "11 out of 660 randomized (double-blinded) study participants." All study participants were told to stop taking the medication.

On July 2011, Merck announced that it had discontinued development of telcagepant.
Q824258
INN
MEDIA
Q1026329
calcitonin gene-related peptide receptor antagonist
Concept
Q133823
migraine
Concept
Q247489
Merck & Co.
ORG
Q212171
rizatriptan
Concept
Q218820
zolmitriptan
Concept
None
Phase IIa
UNK
Q1773974
prophylaxis
Concept
Q305481
alanine transaminase
Concept
Q5675567
Telcagepant
Concept
2009-03-26T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
March 26, 2009
DATE
2011-07-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
July 2011
DATE
-0974^^http://www.w3.org/2001/XMLSchema#decimal
-0974
NUMBER
+11^^http://www.w3.org/2001/XMLSchema#decimal
11
NUMBER
instance of
medical condition treated
medical condition treated